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Abstract – In felids, feline leukemia virus (FeLV) infection results in a variety of outcomes that range from
abortive (virus readily eliminated and never detectable) to progressive infection (persistent viremia and viral
shedding). Recently, a novel outcome was postulated for low FeLV infectious doses. Naı ¨ve cats exposed to
faeces of persistently infected cats seroconverted, indicating infection, but remained negative for provirus
and p27 antigen in blood. FeLV provirus was found in some tissues but not in the bone marrow, infection of
which is usually considered a necessary stage for disease progression. To investigate the impact of low
FeLV doses on young cats and to test the hypothesis that low dose exposure may lead to an unknown
pathogenesis of infection without involvement of the bone marrow, 21 cats were infected oronasally with
variable viral doses. Blood p27, proviral and viral loads were followed until week 20 post-infection. Tissue
proviral loads were determined as well. The immune response was monitored by measuring FeLV whole
virus and p45 antibodies; and feline oncornavirus-associated cell membrane antigen (FOCMA) assay. One
cat showed regressive infection (transient antigenemia, persistent provirus-positivity, and seroconversion)
with provirus only found in some organs at sacriﬁce. In 7 of the 20 remaining cats FOCMA assay positivity
was the only sign of infection, while all other tests were negative. Overall, the results show that FeLV low
dose exposure can result in seroconversion during a presumed abortive infection. Therefore, commonly
used detection methods do not detect all FeLV-infected animals, possibly leading to an underestimation of
the prevalence of infection.
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1. INTRODUCTION
Feline leukemia virus (FeLV) is a retrovirus
of great veterinary importance that was discov-
ered more than 40 years ago [20] and infects
domestic cats and some related small felids
worldwide [18, 22, 32]. An infection with FeLV
may cause disorders of hematopoietic cells, a
state of immunodeﬁciency and fatal neoplasia.
Common symptoms are fever, anaemia, anor-
exia and weight loss. The prevalence of FeLV
infection has been decreasing in the past few
years. In Switzerland, FeLV prevalence was
f o u n dt ob e3 %i nh e a l t h ya n do fu pt o1 3 %
in ill cats [29]. Decreasing prevalence is the
consequence of identiﬁcation and segregation
of infected cats, and of extensive vaccination
programs. However, cases of recurrence keep
occurring and emphasise the importance of an
accurate diagnosis [24]. FeLV is mainly trans-
mitted directly from cat to cat. Transmission
occurs through contact with saliva via licking,
mutual grooming and sharing of food or water
dishes or trough bites [5, 6]. Infectious FeLV
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[8, 34]. FeLV RNA was also detected in urine,
but, its infection potential has not been demon-
s t r a t e ds of a r[ 1]. Pathogenesis is well under-
stood if infectious pressure is high. Infection
starts in the oropharynx where the virus ﬁrst
replicates in tonsils and local lymph nodes
[37], from which the virus spreads to the bone
marrow, thymus, spleen and intestine through
infected lymphocytes. Bone marrow infection
is an important hallmark of FeLV pathogenesis
as the virus replicates extensively in bone
marrow and infects blood precursor cells ﬁrst,
and many organs and tissues thereafter, includ-
ing salivary gland, tonsils, pharyngeal, urinary
bladder, gastric, intestinal, colonic, pancre-
atic and endometrial epithelia, lymph nodes
throughout the body, bone marrow, and spleen
[36, 37]. FeLV infection presents a variety of
outcomes [11, 16–18, 25, 27, 35, 37, 38], which
are inﬂuenced by both host and virus factors.
Known host resistance factors include age and
immune system status. Known virologic factors
are virus strain, subtype and viral infection dose
[18]. The outcome of infection is still a rather
controversial issue. In the past, infection out-
come was classiﬁed as viremic, non-viremic,
and transiently viremic based on results of virus
isolation, immunoﬂuorescence assays and/or
antigen detection [27]. Viremic cats are charac-
terized by continuous expression of p27 viral
antigen. FeLV infection is not contained due
to a lack of FeLV speciﬁc immunity [3, 4, 18].
Viremic cats continuously shed virus, thereby
posing a risk of infection to susceptible cats,
and usually succumb to FeLV-associated dis-
eases (anaemia, immunosuppression, and neo-
plasia). In transiently viremic cats, viremia is
overcome after a few weeks post-infection
(p.i.). However, transiently viremic cats remain
provirus positive [15]. In addition, some non-
viremic cats were shown to have localized
infection characterized by virus replication in
certain tissues, such as mammary, salivary and
urinary epithelium [8, 12, 34]. This additional
form of FeLV infection was termed atypical
or sequestered infection. New sensitive molecu-
lar assays have been described recently for the
use in detection and quantiﬁcation of FeLV
provirus DNA and viral RNA [14, 39, 42],
resulting in a more sensitive measure for FeLV
exposure. The spectrum of host response cate-
gories was reﬁned accordingly. Especially in
p27 negative cats, the outcome should be re-
evaluated based on the presence or absence of
FeLV proviral DNA in blood or bone marrow.
The spectrum of host response categories was
thus reclassiﬁed into: abortive (no virus
detected after exposure), regressive (p27-nega-
tive, provirus positive after or without transient
antigenemia) and progressive (persistently p27
positive, virus isolation, provirus positive,
FeLV RNA positive) [16]. Whether cats that
show no signs of infection (abortive) are truly
immune or just resistant, is still open to debate.
In this context, a very interesting ﬁnding was
that FeLV infection can be transmitted
by contact with faeces [8] with no apparent
viremia and infection involving the bone mar-
row, and constant negativity for proviral DNA
in blood – which would be classiﬁed as abortive
infection. However, in the study of Gomes-
Keller et al. [8] FeLV provirus could be
detected in several organs and the cats showed
seroconversion, indicating that infection indeed
had occurred. It was concluded that under low
infectious pressure a different pathogenesis
m a yt a k ep l a c ei nw h i c hb o n em a r r o wi sn o t
involved. Since FeLV transmission at very
low infection levels appears to be the most nat-
ural way of infection, many cats may show this
yet uncharacterized outcome. Cats that test neg-
ative for FeLV by conventional diagnostic
methods could still have been infected and con-
stitute a relevant portion of the cat population
affected by the virus. The prevalence of FeLV
infection may therefore have been underesti-
mated, a factor that can have important conse-
quences for FeLV control management, e.g. in
Iberian lynxes, which seem to be particularly
susceptible for FeLV infection and for which
a correct estimation of FeLV spreading potential
is of great importance [32]. It was thus the aim
of this study to further characterize the course
of infection after exposure to low infectious
pressure and to test the hypothesis that low
FeLV doses applied to young cats may lead to
seroconversion even when the infection does
not progress through bone marrow. The virus
may not be completely eliminated and a limited
Vet. Res. (2010) 41:17 A. Major et al.
Page 2 of 10 (page number not for citation purpose)viral replication in tissues may lead to a devel-
opment of a weak immune response. Three
groups of 7 cats were exposed to different,
low doses of FeLV. Blood p27 antigen, proviral
DNA and viral RNA were measured in blood
atregular intervalsuntil week 20 p.i.andin pop-
liteal and mesenteric lymph nodes, bone
marrow, spleen, kidney, urinary bladder, lungs,
thymus, myocardium, parotid gland, and
pancreas after euthanasia. Immune response
against FeLV was assessed by the detection of
antibodies by ELISA to FeLV whole virus
and to FeLV p45 (the recombinant env-gene
product), by immunoﬂuorescence assay to
feline oncornavirus-associated cell membrane
antigen (FOCMA), and by Western blot analy-
sis to the separated FeLV components.
2. MATERIALS AND METHODS
2.1. Animals
Twenty-six, 9 weeks-old Speciﬁc Pathogen-Free
(SPF) male kittens were obtained from Liberty
Research, Inc. (Waverly, NY, USA). Animals were
kept under barrier conditions and under optimal etho-
logical and hygienic conditions in one group of 5 cats
(uninfected control group) and three groups of 7 cats
each (group 1K, 10K, and 100K, based on viral
infectious dose). Prior to the beginning of the exper-
iment the cats were tested by PCR, RT-PCR and
serology and shown to be negative for FeLV, FIV,
Herpes-, Corona-, Calici-, Parvovirus and feline
hemotropic mycoplasmas.
2.2. FeLV-A virus challenge
At the age of 16 weeks, each kitten of groups 1K,
10K, and 100K were infected once oronasally with
FeLV-A/Glasgow-1 [19] by introducing 0.2 mL of
virus suspension into each nostril and 0.6 mL into
the mouth. The virus suspension for group 1K con-
tained a total of 1 000 focus-forming units (FFU),
the one for group 10K 10 000 FFU and group 100K
100 0000 FFU. The viral stock origin and infectivity
was the same as described in earlier works [15, 41].
2.3. Sample collection and processing
Blood samples were collected under sedation
(0.01 mg/kgmidazolam(Dormicum
 ,Roche Pharma
AG, Reinach, Switzerland) and 10 mg/kg ketamine
(Narketan
 ,V e ´toquinol AG, Belp, Switzerland)) prior
to challenge at week 7, 5, 3, and then weekly,
startingfromweek0untilweek6 p.i.,laterinbiweekly
intervals until week 20 p.i. Blood samples were
obtainedbyjugularvenipunctureusing5 mLsyringes
and blood was immediately transferred into EDTA-
tubes. 400 lL of EDTA blood was submitted for hae-
matology analysis, 200 lL of EDTA anticoagulated
whole blood were aliquoted for DNA extraction.
Plasma was obtained by centrifuging approximately
2 mL of EDTA blood at 1700· g for 10 min. Blood
and plasma samples were immediately frozen at
80  C until they were processed.
2.4. Detection of proviral DNA and plasma viral
RNA
For determination of FeLV proviral loads, total
nucleicacidswereextractedfromabloodvolumecon-
taining 10
6 white blood cells using the MagNa Pure
LC Total Nucleid Acid Isolation Kit (Roche Diagnos-
tics AG, Rotkreuz, Switzerland). The extracted total
nucleic acids were analyzed by real-time TaqMan
PCR as described in [39]u s i n gt h e2 · TaqMan
  Fast
Universal PCR Master Mix (Applied Biosystems,
FosterCity,CA,USA)onaABI7500sequencedetec-
tion system (Applied Biosystems) and under the fol-
lowing cycling conditions: an initial denaturation of
20 s at 95  C was followed by 45 cycles of 95  C
for 3 s and 60  C for 30 s. For each run, a glyceralde-
hyde-3-phophate dehydrogenase (GAPDH) pseudo-
gene of which one copy is present in the genomic
DNA of feline cells [33] was also quantiﬁed as
described [39]u s i n gt h e2 · TaqMan
  Fast Universal
PCR Master Mix and the same PCR run conditions
as for FeLV provirus. FeLV proviral DNA amounts
were normalized to feline GAPDH by dividing FeLV
copy numbers by fGAPDH copy numbers to calculate
FeLV copies per cell. Viral RNA in plasma samples
was extracted from 200 lL of plasma (either from
5-sample pools or from single samples) using
the MagNa Pure LC Total Nucleic Isolation Kit and
quantiﬁed by real-time TaqMan reverse transcriptase
(RT)-PCR as described [39] using a ABI 7500
sequence detection system.
2.5. Detection of FeLV virus protein p27
by ELISA
T h ep r e s e n c eo fp l a s m aF e L Vp 2 7a n t i g e nw a s
determined using a sandwich ELISA as previously
described [26]. Results are represented as percentages
of a deﬁned positive control (culture supernatant of
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expressing FeLV), which was considered 100%.
Samples reaching > 5% of the positive control signal
were considered positive [14].
2.6. Antibody assays
The plasma samples were also analysed for the
presence of antibodies to FeLV whole virus, to FeLV
p45 (the non-glycosylatedf o r mo fg p 7 0s u r f a c eu n i t
of the envelope glycoprotein), and to FOCMA.
Anti-FeLV p45 and anti-FeLV whole virus antibodies
were measured by ELISA as described [21, 25],
using 100 ng of p45/well and 100 ng of gradient
puriﬁed FL-74 FeLV, respectively. Plasma was used
at a dilution of 1:200 and antibody levels assessed
by comparison with predeﬁned control antisera
[25]. Antibody to FOCMA was measured at week
0 and week 20 p.i., by indirect cell membrane immu-
noﬂuorescence as described [2]. FL-74 cell culture
medium was tested for the absence of FCV, FHV,
FPV, FCoV, FIV, hemotropic mycoplasma and
presence of FeLV by RT-PCR/PCR as described
[9, 13, 23, 31, 39, 44, 45]. The culture was consis-
tently free of the unwanted contaminants. The cat
sera were titrated at 4-fold dilutions from 1:4 to
1:256. Samples showing a minimal titre of 1:4 were
considered to be FOCMA positive. In addition,
samples from week 3 and week 20 p.i. were exam-
ined for the presence of antibodies to FeLV gp70,
p27 and p15(E) [26, 30] by Western blot analysis
as described [28].
2.7. Detection of FeLV provirus and virus
isolation from tissues and bone marrow
Cats of group 10K and group 100K were eutha-
nized at week 20, and tissue samples from popliteal
and mesenteric lymph nodes, bone marrow, spleen,
kidney, urinary bladder, lungs, thymus, myocardium,
parotid gland, and pancreas were collected within
30 min post-mortem. Samples were snap-frozen in
liquid nitrogen. Ten mg of tissue were used for the
extraction of DNA using MagNA Pure LC DNA
Isolation Kit II (Tissue kit, Roche Diagnostics).
FeLV provirus was quantiﬁed by real-time PCR as
described [39, 40]. To guarantee a comparable sensi-
tivity, samples yielding less than 15 000 fGAPDH
copies per reaction were re-extracted until a suitable
concentration was reached. In addition, samples were
collected under sterile conditions from mesenteric
lymph node, urinary bladder, lungs, thymus, and
myocardium for virus isolation. Tissue samples were
co-cultured with FEA cells and supernatants of the
co-cultures collected at days 4, 8, 12, 16, 20, 24,
and 28 post-inoculation were tested for p27 antigen
by ELISA as described [7]. Bone marrow samples
were cultured in medium and supernatants collected
at days 18 and 21 were used for total nucleic acid iso-
lation (MagNA Pure LC Total Nucleic Acid Isolation
Kit, Roche Diagnostics) and samples were tested for
the presence of FeLV RNA. Additionally, superna-
tants were tested by p27 ELISA [26].
2.8. Statistics
Statistical analyses were carried out using
R software version 2.9.0. (The R Foundation for
Statistical Computing, Vienna, Austria). Longitudinal
effects (time) on antibody titres of the different
groups were compared to each other by multivariate
analysis of variance (MANOVA). A p value < 0.05
was considered to be statistically signiﬁcant.
3. RESULTS
3.1. FeLV DNA and RNA detection in blood
With one exception, cats did not become
provirus positive at any time point tested. The
one cat (JCR2) that was found to be positive
belonged to the group challenged with the high-
est of the three doses of FeLV (100 000 FFU).
Proviral DNAwas detected from week 2 p.i. on
with a peak at week 3 (3.33 copies/cell)
(Fig. 1). Similarly, viral RNA was consistently
detected only in samples of the provirus-posi-
tive cat (JCR2) until week 12 and additionally
at week 18 once more. The highest viral RNA
load measured was at week 2 p.i. (Ct-value of
22.95, Fig. 1). Viral RNA was not detectable
in pooled plasma samples (5 samples each
pool) of any of the provirus-negative cats at
week 0, 10, and 20 p.i. In addition, samples
from week 2, 3, and 4 were tested individually,
as the viral RNA peak usually occurs in this
time period; the results were negative, too.
3.2. Detection of p27 in plasma
p27 antigen was detected in plasma of one
(JCR2) of the 26 cats tested. This cat became
transiently positive from week 3 p.i. to week
4p . i .( Fig. 1). p27 was not detectable at any
time point in all other cats.
Vet. Res. (2010) 41:17 A. Major et al.
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By measuring antibodies against FeLV p45
and whole virus by ELISA, seroconversion
was observed in one cat. In the p45 ELISA, this
cat (JCR2) had a positive response throughout
weeks 8 to 20 with a peak of 26% of the posi-
tive control at week 14, and throughout weeks
4 to 20 with a peak of 54% of the positive con-
trol at week 20 in the FeLV whole virus ELISA
(data not shown). Analysis of the remaining
animals showed no statistically relevant differ-
ence between the groups in p45 as well as
whole virus ELISA (PMANOVA 0.53 and 0.47,
respectively Figs. 2 and 3). Prior to challenge,
all samples were negative for the presence of
antibodies directed against FOCMA. At week
20 p.i., antibodies to FOCMA were detected
in 4 cats (KCT1, JCU3, JCO2, JCP1, 57%) of
group 10K and 4 (KDA1, JCR2, KCQ1,
JCS1, 57%) cats of group 100K. Of these 8
cats, the PCR-positive cat (JCR2) reached the
highest titre (1:64), the other 7 cats developed
antibody titres which ranged from 1:4 to 1:16.
No negative control group and group 1K animal
had a detectable titre (Tab. I). In Western blot
analysis, sera from 2 cats of group 10K
(JCU3, JCS2) showed a weak reactivity to the
upper band of the p15(E) protein at a serum
dilution of 1:40 as well as at 1:100. However,
t h es a m ec a t ss h o w e ds o m er e a c t i v i t yt ot h e
upper band of p15(E) already at week 0 p.i.
(Fig. 4). In the PCR-positive cat (JCR2) the
presence of antibodies against FeLV was con-
ﬁrmed at a dilution of 1:100. All other cats from
group 100K, 10K and 1K had either a com-
pletely negative Western blot pattern or showed
cross-reactive bands already present at week
3 (cats KDA1 and JCS2, Fig. 4).
3.4. Detection of FeLV DNA sequences
and virus isolation from tissues
At week 20 post-challenge, cats of groups
10K and 100K were euthanized and different
tissue samples were collected and analysed for
the presence of FeLV DNA sequences. Popli-
teal and mesenteric lymph nodes, bone marrow,
spleen, kidney, urinary bladder, lungs, thymus,
myocardium, parotid gland, and pancreas were
tested. FeLV DNA sequences were found in
organs of the cat (JCR2) positive for FeLV
provirus in blood. The copy numbers were in
average very low and ranged from 5.6 to
704.25 copies/reaction (3.4 · 10
5 to 0.0024
copies/cell,datanotshown).Thepopliteallymph
node showed the highest FeLV proviral load
(0.0024 copies/cell). No FeLV DNA sequences
were detected in tissue samples of all other
cats. Virus isolation from urinary bladder,
myocardium,lungs,mesentericlymphnode,thy-
mus, and bone marrow was negative for all cats.
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Figure 1. Proviral DNA, viral RNA, and plasma p27 loads from the persistent PCR-positive cat JCR2
measured at regular intervals until week 20 p.i. Provirus and virus loads are expressed as 45 minus the cycle
threshold (Ct) values measured. p27 results are represented as percentage in comparison to a positive control
(FL-74 lymphoblastoid cell culture supernatant), which was considered to be 100%. Cat JCR2, found to be
consistently provirus positive, showed a regressive infection with transient antigenemia.
Seroconversion and low dose FeLV exposure Vet. Res. (2010) 41:17
(page number not for citation purpose) Page 5 of 10Figure 2. Box-plot results obtained measuring antibodies directed to FeLV p45 over the whole observation
period as percentage of the positive control. The PCR-positive cat of group 100K was excluded. No
statistically relevant difference between the groups was observed. Open boxes: negative controls, crossed
boxes: 1K group, dotted boxes: 10K group, hatched boxes: 100K group. Outliers are depicted by a dot.
Figure 3. Antibodies directed to FeLV whole virus. Results are expressed as percentage of a positive
control. The PCR-positive cat of group 100K was excluded. No statistically relevant difference between the
groups was observed. Open boxes: negative controls, crossed boxes: 1K group, dotted boxes: 10K group,
hatched boxes: 100K group. Outliers are depicted by a dot.
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The aim of this study was to investigate to
what degree cats can become infected by low
dose oral FeLV infection without detectable
involvement of the bone marrow. Even though
FeLV prevalence has reportedly decreased dur-
ing the past years, FeLV is still among the most
important infectious diseases of cats. Hence, a
deep knowledge of all aspects of FeLV patho-
genesis and biology is essential. Recently, a
novel course of infection was postulated that
Table I. Indirect FL-74 FOCMA immunoﬂuorescence pre- and post-exposure test to low FeLV doses.
Numbers of the titre column represent the antibodies titre, numbers in the groups columns represent the
number of cats with the respective titre.
Titre Negative control Group 1K Group 10K Group 100K
Week 0 Week 20 Week 0 Week 20 Week 0 Week 20 Week 0 Week 20
Negative 77777373
1 : 4 00000203
1:16 00000200
1:64 00000001
Figure 4. Western blot analysis using plasma samples from week 3 (prior to challenge) and week 20 p.i.
(cats group 100K and two of group 10K). The ﬁrst 3 strips to the left were incubated with monoclonal
antibodies against gp70, p27 and p15(E), respectively, to characterize the respective viral proteins. Serum
obtained from a pool of immune cats used as a positive control. Cat JCU3 and cat JCS2 (group 10K) show a
weak reaction with the upper band of the p15(E) protein. JCR2 shows antibodies to all FeLV proteins. In all
other cats, responses to any FeLV proteins could not be detected. (c) bands with expected length. All
samples were tested under the same assay conditions.
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phase in which bone marrow is infected. In this
alternative course, cats exposed to low loads of
virus via faecal route seroconverted without
involvement of bone marrow and without
showing any other sign of infection [8]. Under
ﬁeld conditions, exposure to small virus loads is
expected to be frequent due to superﬁcial direct
contact with viremic cats shedding FeLV or
indirectly through contact with excretions pro-
duced by viremic cats. Thus, many cats may
show this newly recognized outcome. Since
experimental infection had to mimic the natural
mode of transmission trough faeces or saliva, in
the present study we challenged the cats orona-
sally with viral loads that, based on published
results [10] and on our experience, would
induce abortive or regressive infection. Indeed,
only one cat belonging to the group with the
highest challenge dose showed regressive infec-
tion. For all other cats, abortive infection would
have been assigned based on commonly used
methods [16]. In this study, we demonstrated
that a single oronasal exposure to FeLV as
low as 10 000 FFU is sufﬁcient to elicit an
antibody response and to lead to seroconversion
in at least 18% (lower 95% conﬁdence interval
of the distribution) of the cats, demonstrating
that the postulated alternative course of infec-
tion may occur in a considerable portion of
the animals. We propose to designate this out-
come of infection as abortive infection with
seroconversion. No hallmark of infection was
observed in the cats that received the smallest
of the three doses (1 000 FFU), for which indi-
vidual local innate immunity might have been
enough to contain viral replication and to lead
to abortive infection without a detectable adap-
tive immune response. However, under ﬁeld
conditions, multiple exposures in the range of
1 000 FFU or lower may occur giving rise to
seroconversion or even provirus positivity.
Considering that the assay for proviral DNA
is able to detect one copy per reaction, we
believe that the consistent PCR-negativity in
blood of the cats that seroconverted is a strong
indicator for the absence of bone marrow infec-
tion, a conﬁrmation that an alternative course of
infection may indeed exist, where the bone mar-
row is not involved [1]. FeLV provirus may still
be integrated into the genome of the cells of
some tissues but, in most cases, at levels
beyond detection. In the study presented here,
FeLV DNA sequences were not detectable in
the organs tested. However, the presence of
FeLV provirus in tissues other than the ones
we analysed can not be excluded and should
be investigated further. In localized infection
whereFeLVreplicationisconﬁnedtocertaintis-
sues, presence of plasma viral RNA loads is
regarded a sensitive parameter for infection.
RNA loads reﬂect ongoing viral replication
somewhereinthecat’sbodyeveninsequestered
places. However, detection of RNA is generally
less frequent than that of proviral DNA [39].
Seroconversion was observed by use of the
FL-74 cell membrane immunoﬂuorescence test.
This assay originally had been designated FO-
CMA test and was thought to detect antibodies
at a non-virion tumour-associated antigen [2].
Later,itbecameclearthattheFOCMAphenom-
enon can be explained not by a tumour speciﬁc
antigen but by viral proteins including FeLV
p15(E),gag-polyproteinsandgp70ofFeLVsub-
typeCpresentontheFL-74cellmembrane[43].
The FL-74 cell membrane immunoﬂuorescence
test seems to be the most sensitive method to
detect seroconversion compared to ELISA and
Western blotting. This may be due in part to
the less stringent test conditions, which allow
antibodieswithlowerafﬁnitytobindtotheirepi-
topes, and in part to the fact that in the FOCMA
assaythebindingtargetsarepresentedinanative
conformation, thus allowing a better binding of
conformation-speciﬁc antibodies. Induction of
cytotoxic T-cells or virus-neutralizingantibodies
by oral low dose infection, or Th1 cytokine
expression that might have been induced by
the experimental infection were not measured.
Instead, antibody response was used as marker
ofinfection.Itisuncleartowhatdegreethealter-
native pathway may be relevant to the spread of
FeLVinfection. We speculate that in most cases
cats will overcome the infection for good. In
very few cases – when the infected cats undergo
immunosuppression due e.g. to concomitant
FIV infection – full-blown FeLV infection with
bone marrow involvement and viral shedding
may develop. It will be important to determine
to what extent this may occur.
Vet. Res. (2010) 41:17 A. Major et al.
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additional evidence for the existence of an alter-
native FeLVinfection course that leads to devel-
opmentofantibodieswithoutinvolvementofthe
bone marrow. The results may be important for
the surveillance of the FeLV status of a cattery
or a cat population. Most likely a cattery cannot
be considered free of FeLVas long as cats with
FeLV-reactiveantibodiesarepresent.Thepoten-
tial for overt infection cannot be neglected.
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